Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Feb 8

PMID 32028635

Citations 34

Authors

Caterina Vacchi

Marco Sebastiani

Giulia Cassone

Stefania Cerri

Giovanni Della Casa

Carlo Salvarani

Andreina Manfredi

Affiliations

Soon will be listed here.

Abstract

Interstitial lung disease (ILD) is one of the most serious pulmonary complications of connective tissue diseases (CTDs) and it is characterized by a deep impact on morbidity and mortality. Due to the poor knowledge of CTD-ILD's natural history and due to the difficulties related to design of randomized control trials, there is a lack of prospective data about the prevalence, follow-up, and therapeutic efficacy. For these reasons, the choice of therapy for CTD-ILD is currently very challenging and still largely based on experts' opinion. Treatment is often based on steroids and conventional immunosuppressive drugs, but the recent publication of the encouraging results of the INBUILD trial has highlighted a possible effective and safe use of antifibrotic drugs as a new therapeutic option for these subjects. Aim of this review is to summarize the available data and recent advances about therapeutic strategies for ILD in the context of various CTD, such as systemic sclerosis, idiopathic inflammatory myopathy and Sjogren syndrome, systemic lupus erythematosus, mixed connective tissue disease and undifferentiated connective tissue disease, and interstitial pneumonia with autoimmune features, focusing also on ongoing clinical trials.

Citing Articles

Successful Management of Rapidly Progressive Interstitial Pneumonia With Autoimmune Features in an Elderly Patient: A Case Report.

Tanaka Y, Ohta R, Sano C Cureus. 2025; 17(1):e78303.

PMID: 40026994 PMC: 11872281. DOI: 10.7759/cureus.78303.

Microvascular alterations of the ocular surface and retina in connective tissue disease-related interstitial lung disease.

Chen L, Kang M, Wang J, Xu S, Chen C, Wei H Int J Ophthalmol. 2024; 17(10):1869-1879.

PMID: 39430022 PMC: 11422355. DOI: 10.18240/ijo.2024.10.14.

Roles of TRIM21/Ro52 in connective tissue disease-associated interstitial lung diseases.

Gong X, He S, Cai P Front Immunol. 2024; 15:1435525.

PMID: 39165359 PMC: 11333224. DOI: 10.3389/fimmu.2024.1435525.

Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.

Kotani T, Saito T, Suzuka T, Matsuda S Inflamm Regen. 2024; 44(1):35.

PMID: 39026275 PMC: 11264739. DOI: 10.1186/s41232-024-00348-z.

The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.

Puiu R, Motoc N, Lucaciu S, Ruta M, Rajnoveanu R, Todea D Biomolecules. 2024; 14(3).

PMID: 38540667 PMC: 10968628. DOI: 10.3390/biom14030247.

References

Tellus M, Buchanan R . Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporine. Br J Rheumatol. 1995; 34(12):1187-8. DOI: 10.1093/rheumatology/34.12.1187. View

Khanna D, Denton C, Jahreis A, van Laar J, Frech T, Anderson M . Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016; 387(10038):2630-2640. DOI: 10.1016/S0140-6736(16)00232-4. View

Eyraud A, Scouppe L, Barnetche T, Forcade E, Lazaro E, Duffau P . Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. Br J Dermatol. 2017; 178(3):650-658. DOI: 10.1111/bjd.15993. View

Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C . Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015; 14(11):1072-8. DOI: 10.1016/j.autrev.2015.07.008. View

Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A . Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016; 121:91-99. DOI: 10.1016/j.rmed.2016.10.019. View

Nadashkevich O, Davis P, Fritzler M, Kovalenko W . A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2005; 25(2):205-12. DOI: 10.1007/s10067-005-1157-y. View

Miura Y, Saito T, Fujita K, Tsunoda Y, Tanaka T, Takoi H . Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(3):235-8. View

Gerbino A, Goss C, Molitor J . Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2007; 133(2):455-60. DOI: 10.1378/chest.06-2861. View

Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas A . Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012; 8(7):399-411. DOI: 10.1038/nrrheum.2012.53. View

10.

Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli T, Simopoulou T . A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2016; 46(5):625-631. DOI: 10.1016/j.semarthrit.2016.10.003. View

11.

Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L . Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010; 29(10):1167-8. DOI: 10.1007/s10067-010-1498-z. View

12.

Parambil J, Myers J, Lindell R, Matteson E, Ryu J . Interstitial lung disease in primary Sjögren syndrome. Chest. 2006; 130(5):1489-95. DOI: 10.1378/chest.130.5.1489. View

13.

Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M . Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis. 2006; 66(3):351-7. PMC: 1856024. DOI: 10.1136/ard.2006.057919. View

14.

Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B . Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018; 378(1):35-47. PMC: 5846574. DOI: 10.1056/nejmoa1703327. View

15.

Andersson H, Sem M, Lund M, Aalokken T, Gunther A, Walle-Hansen R . Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015; 54(8):1420-8. DOI: 10.1093/rheumatology/kev004. View

16.

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K . Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(9):1713-9. DOI: 10.1093/rheumatology/keq149. View

17.

Shoji T, Bando T, Fujinaga T, Okubo K, Yukawa N, Mimori T . Living-donor lobar lung transplantation for interstitial pneumonia associated with dermatomyositis. Transpl Int. 2010; 23(5):e10-1. DOI: 10.1111/j.1432-2277.2010.01066.x. View

18.

Torres C, Belmonte R, Carmona L, Gomez-Reino F, Galindo M, Ramos B . Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006; 39(3):205-15. DOI: 10.1080/08916930600622603. View

19.

Suissa S, Ernst P . The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations. Eur Respir J. 2016; 47(1):344-5. DOI: 10.1183/13993003.01274-2015. View

20.

Chen I, Wu Y, Lin C, Fan K, Luo S, Ho H . Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009; 28(6):639-46. DOI: 10.1007/s10067-009-1110-6. View